BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30427091)

  • 1. Health-related quality of life in paediatric haemophilia B patients treated with rIX-FP.
    von Mackensen S; Shah J; Seifert W; Kenet G
    Haemophilia; 2019 Jan; 25(1):45-53. PubMed ID: 30427091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.
    Hermans C; Marino R; Lambert C; Mangles S; Sommerer P; Rives V; Maro G; Malcangi G
    Adv Ther; 2020 Jun; 37(6):2988-2998. PubMed ID: 32333327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High adherence to prophylaxis regimens in haemophilia B patients receiving rIX-FP: Evidence from clinical trials and real-world practice.
    Mancuso ME; Oldenburg J; Boggio L; Kenet G; Chan A; Altisent C; Seifert W; Santagostino E
    Haemophilia; 2020 Jul; 26(4):637-642. PubMed ID: 32542961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP).
    Santagostino E
    Thromb Res; 2016 May; 141 Suppl 3():S5-8. PubMed ID: 27288064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
    Négrier C; Abdul Karim F; Lepatan LM; Lienhart A; López-Fernández MF; Mahlangu J; Pabinger I; Li Y; Wolko D; Voigt C; Jacobs I; Santagostino E
    Haemophilia; 2016 Jul; 22(4):e259-66. PubMed ID: 27333467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulation Factor IX (Recombinant), Albumin Fusion Protein (Albutrepenonacog Alfa; Idelvion
    Lyseng-Williamson KA
    Drugs; 2017 Jan; 77(1):97-106. PubMed ID: 27988873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product.
    Chowdary P; Kearney S; Regnault A; Hoxer CS; Yee DL
    Haemophilia; 2016 Jul; 22(4):e267-74. PubMed ID: 27352908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial.
    Kenet G; Chambost H; Male C; Lambert T; Halimeh S; Chernova T; Mancuso ME; Curtin J; Voigt C; Li Y; Jacobs I; Santagostino E;
    Thromb Haemost; 2016 Sep; 116(4):659-68. PubMed ID: 27583313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Safety and Efficacy of Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Previously Treated Pediatric Patients with Hemophilia B: Results from a Phase 3b Extension Study.
    Kenet G; Chambost H; Male C; Halimeh S; Lambert T; Li Y; Seifert W; Santagostino E
    Thromb Haemost; 2020 Apr; 120(4):599-606. PubMed ID: 32185782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B.
    Guillet B; Yan S; Hooper B; Drelich D; Steenkamp J; Tomic R; Mancuso ME
    Adv Ther; 2024 Feb; 41(2):649-658. PubMed ID: 38070040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy.
    Oldenburg J; Yan S; Maro G; Krishnarajah G; Tiede A
    Curr Med Res Opin; 2020 Jan; 36(1):9-15. PubMed ID: 31469321
    [No Abstract]   [Full Text] [Related]  

  • 12. IDEAL study: A real-world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX-FP) in patients with haemophilia B in Italy.
    Tagliaferri A; Molinari AC; Peyvandi F; Coppola A; Demartis F; Biasoli C; Borchiellini A; Cultrera D; De Cristofaro R; Daniele F; Giordano P; Marchesini E; Margaglione M; Marino R; Pollio B; Radossi P; Santoro C; Santoro RC; Siragusa S; Sottilotta G; Tosetto A; Piscitelli L; Villa MR; Zanon E; Finardi A; Schiavetti I; Vaccari D; Castaman G
    Haemophilia; 2023 Jan; 29(1):135-144. PubMed ID: 36423202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
    Zhang Y; Roberts J; Bensen-Kennedy D; Jacobs I; Santagostino E; Voigt C; Feussner A; Morfini M; Sidhu J
    J Thromb Haemost; 2016 Nov; 14(11):2132-2140. PubMed ID: 27513989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PROLONG-9FP clinical development program--phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).
    Santagostino E
    Thromb Res; 2013 Mar; 131 Suppl 2():S7-10. PubMed ID: 23537724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX-FP in the PROLONG-9FP clinical trial program.
    Laws HJ; Fukutake K; Lopez-Fernandez MF; Li Y; Seifert W; Tagliaferri A
    Eur J Haematol; 2023 Aug; 111(2):293-299. PubMed ID: 37232041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B.
    Gill JC; Roberts J; Li Y; Castaman G
    Haemophilia; 2019 May; 25(3):e219-e222. PubMed ID: 30866086
    [No Abstract]   [Full Text] [Related]  

  • 17. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.
    Martinowitz U; Lissitchkov T; Lubetsky A; Jotov G; Barazani-Brutman T; Voigt C; Jacobs I; Wuerfel T; Santagostino E
    Haemophilia; 2015 Nov; 21(6):784-90. PubMed ID: 25990590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simplifying surgery in haemophilia B: Low factor IX consumption and infrequent infusions in surgical procedures with rIX-FP.
    Curtin J; Santagostino E; Karim FA; Li Y; Seifert W; Négrier C
    Thromb Res; 2020 Apr; 188():85-89. PubMed ID: 32109773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.
    Nolte MW; Nichols TC; Mueller-Cohrs J; Merricks EP; Pragst I; Zollner S; Dickneite G
    J Thromb Haemost; 2012 Aug; 10(8):1591-9. PubMed ID: 22726310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B.
    Martinowitz U; Lubetsky A
    Thromb Res; 2013 Mar; 131 Suppl 2():S11-4. PubMed ID: 23537721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.